Journal
ANTI-CANCER DRUGS
Volume 16, Issue 5, Pages 495-500Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00001813-200506000-00004
Keywords
5-fluorouracil; chemotherapy; colon; cyclooxygenase-2; esophageal cancer; irinotecan
Categories
Ask authors/readers for more resources
Inhibition of cyclooxygenase (COX)-2 has been associated with reduced growth of malignant cells. Current therapy of gastrointestinal carcinomas involves the use of 5-fluorouracil (5-FU)-based chemotherapy and we have therefore studied the effect of this agent on the expression of COX-2. COX-2 expression was measured by quantitative RT-PCR in biopsies from a series of 14 esophageal carcinomas, six of which had paired samples taken before and after chemotherapy, and in tumor-derived cells exposed to 5-FU in vitro from a series of 44 tumors, including breast, ovarian, esophageal and colonic carcinomas. COX-2 expression was increased by exposure to 5-FU or 5-FU combination chemotherapy in all the tumor types studied, whether measured in biopsies taken before and after 5-FU-based chemotherapy (4-fold increase, p < 0.015) or in primary cells exposed to drugs in vitro (24-fold increase, p < 0.001). A modest increase of COX-2 mRNA was also seen after in vitro treatment of cells with cisplatin. In contrast, doxorubicin and paclitaxel caused no up-regulation in vitro, while irinotecan caused inhibition of COX-2 (2.7-fold decrease, p < 0.01). These data provide a molecular rationale for clinical trials of combination chemotherapy with COX-2 inhibitors. Anti-Cancer Drugs 16:495-500 (c) 2005 Lippincott Williams & Wilkins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available